AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23813757 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin intrinsic fluorescence (SIF) in the intensive treatment group
Number of subjects: 1185
Study 23813757 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin intrinsic fluorescence (SIF) in the conventional treatment group
Number of subjects: 1185
Study 23813900 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine-based PBPC transplantation
Number of subjects: 56
Study 23815472 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF+PI/r
Number of subjects: 150
Study 23815472 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study 23815563 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI Common Data Elements (TBI-CDEs)
Number of subjects: 650
Study 23815876 — intervention group
Group type: EXPERIMENTAL
Intervention: FOXP1 gene transcript in lymphoblastoid cell lines (LCL)
Number of subjects: 16
Study 23815981 — intervention group
Group type: EXPERIMENTAL
Intervention: FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody in combination with donor lymphocyte infusion (DLI)
Number of subjects: 24
Study 23816016 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg twice a day for 1 month for patients ≥70 kg; 0.5 mg once for patients <70 kg or intolerant)
Number of subjects: 360
Study 23816016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 23816016 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 360
Study 23816032 — intervention group
Group type: COMPARATOR
Intervention: No CAD
Number of subjects: 917
Study 23816032 — intervention group
Group type: COMPARATOR
Intervention: Nonobstructive CAD
Number of subjects: 917
Study 23816032 — intervention group
Group type: COMPARATOR
Intervention: Obstructive CAD
Number of subjects: 917
Study 23816032 — intervention group
Group type: EXPERIMENTAL
Intervention: WISE CAD severity score >10
Number of subjects: 917
Study 23816330 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended criteria organs (BMI 30-34 or donor age 50-60)
Number of subjects: 0
Study 23816330 — intervention group
Group type: COMPARATOR
Intervention: Standard criteria organs (BMI <30 and donor age <50)
Number of subjects: 0
Study 23816920 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (n = 4), administered every 2-4 weeks over 24 weeks
Number of subjects: 8
Study 23816920 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 4), administered every 2-4 weeks over 24 weeks
Number of subjects: 8
Study 23816963 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 50 mg per day
Number of subjects: 62
Study 23817375 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) at 50 mg daily for 5 days followed by DTG with prednisone at 60 mg daily for 10 days (5 days high-dose followed by 5-day taper)
Number of subjects: 12
Study 23817375 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) at 50 mg daily for 5 days
Number of subjects: 12
Study 23817375 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir and prednisone coadministration
Number of subjects: 12
Study 23817567 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 0
Study 23817577 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-derived collateral flow index (CFIp) during resting conditions
Number of subjects: 30
Study 23817577 — intervention group
Group type: EXPERIMENTAL
Intervention: Toe oxygen saturation (Sao2) during resting conditions
Number of subjects: 30
Study 23817577 — intervention group
Group type: EXPERIMENTAL
Intervention: CFIp during exercise
Number of subjects: 30
Study 23817577 — intervention group
Group type: EXPERIMENTAL
Intervention: Sao2 during exercise
Number of subjects: 30
Study 23817577 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain or cramps/tired muscles during exercise
Number of subjects: 30
Study 23817577 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship between CFIp and pain-free time span
Number of subjects: 30
Study 23817721 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell-based vaccine targeting CSCs
Number of subjects: 7
Study 23817721 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 7
Study 23817974 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-285 (400 mg twice daily)
Number of subjects: 54
Study 23818263 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadjuvant influenza A H1N1 vaccine in juvenile SLE patients
Number of subjects: 118
Study 23818263 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls vaccinated with nonadjuvant influenza A H1N1 vaccine
Number of subjects: 118
Study 23818263 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvenile SLE patients with SLEDAI-2K score ≥8
Number of subjects: 118
Study 23818263 — intervention group
Group type: EXPERIMENTAL
Intervention: SLEDAI-2K score ≥8 as a factor for nonseroconversion
Number of subjects: 118
Study 23818490 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese African-American girls
Number of subjects: 76
Study 23818490 — intervention group
Group type: COMPARATOR
Intervention: Latina girls
Number of subjects: 76
Study 23819100 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage (group 2)
Number of subjects: 400
Study 23819100 — intervention group
Group type: COMPARATOR
Intervention: Nondrainage (group 1)
Number of subjects: 400
Study 23819769 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-thumb encircling hands technique
Number of subjects: 1
Study 23819769 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-thumbs direct compression technique
Number of subjects: 1
Study 23819769 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic one-hand technique with sternal accelerometer
Number of subjects: 1
Study 23819769 — intervention group
Group type: EXPERIMENTAL
Intervention: Restoration of spontaneous circulation (ROSC)
Number of subjects: 1
Study 23820296 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar Fusion (LF)
Number of subjects: 666
Study 23820296 — intervention group
Group type: COMPARATOR
Intervention: Conservative Treatment (Control)
Number of subjects: 666
Study 23820600 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected women
Number of subjects: 33
Study 23821658 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: -1
Study 23822525 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial triage priority (high vs. low priority) adjudicated by the attending ED physician at ED discharge
Number of subjects: 6000
Study 23822525 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse 30 day outcome (death or intensive care unit admission)
Number of subjects: 6000
Study 23822525 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-acute care needs after hospital discharge (transfer to a post-acute care institution)
Number of subjects: 6000
Study 23822525 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to first physician contact
Number of subjects: 6000
Study 23822525 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to initiation of adequate medical therapy
Number of subjects: 6000
Study 23822525 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to social worker involvement
Number of subjects: 6000
Study 23822525 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of hospital stay
Number of subjects: 6000
Study 23822525 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for discharge delays
Number of subjects: 6000
Study 23822525 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient's satisfaction with care
Number of subjects: 6000
Study 23822525 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall hospital costs
Number of subjects: 6000
Study 23822525 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient's care needs after returning home
Number of subjects: 6000
Study 23822537 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat treatment
Number of subjects: 129
Study 23822537 — intervention group
Group type: EXPERIMENTAL
Intervention: TARC reductions > median at C1D15
Number of subjects: 129
Study 23823198 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-16
Number of subjects: 130
Study 23823198 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6
Number of subjects: 130
Study 23823198 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of interleukin-16 and 10-minute Apgar score
Number of subjects: 130
Study 23823332 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,500 sporozoites intradermally (ID)
Number of subjects: 18
Study 23823332 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,500 sporozoites intramuscularly (IM)
Number of subjects: 18
Study 23823332 — intervention group
Group type: EXPERIMENTAL
Intervention: 25,000 sporozoites intramuscularly (IM)
Number of subjects: 18
Study 23823978 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 402
Study 23824037 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate infusion in critically ill patients with AKI
Number of subjects: 12
Study 23824037 — intervention group
Group type: COMPARATOR
Intervention: Citrate infusion in healthy volunteers
Number of subjects: 12
Study 23824312 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention facilitating early cancer rehabilitation by involvement of the general practitioner (GP) soon after diagnosis.
Number of subjects: 955
Study 23824312 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care without the intervention).
Number of subjects: 955
Study 23824363 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT) delivering accelerated partial breast irradiation (APBI) at a dose of 38.5 Gy in 10 equal fractions delivered twice daily.
Number of subjects: 136
Study 23824723 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower ratio of n-6 to n-3 fatty acids
Number of subjects: 70
Study 23824723 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intake of n-3 fatty acids with high n-6 to n-3 ratio
Number of subjects: 70
Study 23824723 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower intake of n-3 and lower intake of n-6 with low n-6 to n-3 ratio
Number of subjects: 70
Study 23824723 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean n-3 and mean n-6 intakes
Number of subjects: 70
Study 23824723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of n-6 to n-3
Number of subjects: 70
Study 23824978 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (CAB) treatment after 24 months
Number of subjects: 40
Study 23824978 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (CAB) treatment after 60 months
Number of subjects: 40
Study 23824978 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative CAB dose
Number of subjects: 40
Study 23824978 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolactin levels normalization
Number of subjects: 40
Study 23826832 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar support pillow
Number of subjects: 28
Study 23826832 — intervention group
Group type: COMPARATOR
Intervention: Standard chair
Number of subjects: 28
Study 23827036 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine culture for mycobacteria during bronchoscopy
Number of subjects: 362
Study 23827886 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment for 10 weeks
Number of subjects: 1877
Study 23827886 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic ancestry analysis
Number of subjects: 1877
Study 23827886 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic and baseline clinical factors
Number of subjects: 1877
Study 23827886 — intervention group
Group type: EXPERIMENTAL
Intervention: Race (self-reported)
Number of subjects: 1877
Study 23828026 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 23828202 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient elastography (TE) during VOC
Number of subjects: 23
Study 23828202 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical markers during VOC
Number of subjects: 23
Study 23828202 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy inflammation at steady-state
Number of subjects: 23
Study 23828202 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricuspid regurgitation velocity (TRV) at steady-state
Number of subjects: 23
Study 23828252 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,020 mg of ferumoxytol administered over 15 min
Number of subjects: 60
Study 23829205 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c-MEAN
Number of subjects: 8290
Study 23829205 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c-SD
Number of subjects: 8290
Study 23829205 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c-MEAN and HbA1c-SD
Number of subjects: 8290
Study 23829485 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) infusion of veltuzumab (80-320 mg)
Number of subjects: 41
Study 23829485 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) injections of veltuzumab (80-320 mg)
Number of subjects: 41
Study 23829485 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IV and SC administration of veltuzumab
Number of subjects: 41
Study 23829485 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) injections of veltuzumab
Number of subjects: 41
Study 23829485 — intervention group
Group type: EXPERIMENTAL
Intervention: Veltuzumab treatment
Number of subjects: 41
Study 23829956 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipedicled nerve flap with nerve graft from the dorsal branch of the digital nerve
Number of subjects: 9
Study 23830159 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (Ach) infusion (10(-6) to 10(-4))
Number of subjects: 25
Study 23830159 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion (200 μg)
Number of subjects: 25
Study 23830564 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual segmentation and computer-assisted techniques for detecting drusen regression
Number of subjects: 58
Study 23830564 — intervention group
Group type: COMPARATOR
Intervention: Fundus photography
Number of subjects: 58
Study 23830564 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundus autofluorescence (FAF) imaging
Number of subjects: 58
Study 23831416 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (cisplatin 80 mg/m(2) on day 1, cisplatin 70 mg/m(2) on days 8, 15, 29, 36, 43, 57, 64; doxorubicin 30 mg/m(2) on days 8, 9, 36, 37, 57, 58) followed by surgery.
Number of subjects: 62
Study 23831416 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical removal of all remaining tumour lesions if feasible.
Number of subjects: 62
Study 23831416 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy (doxorubicin 20 mg/m(2) on days 1, 2, 22, 23, 43, 44; carboplatin AUC 6·6 mg/mL per min on days 1, 22, 43) for patients who did not receive cycle B.
Number of subjects: 62
Study 23831416 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment regimen (including preoperative and postoperative chemotherapy).
Number of subjects: 62
Study 23831596 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous myoblast transplantation
Number of subjects: 12
Study 23831734 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0865 25-75 mg/day
Number of subjects: 2875
Study 23831734 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 20 or 40 mg/day
Number of subjects: 2875
Study 23831756 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oral ∆(9)-tetrahydrocannabinol (THC)/day
Number of subjects: 11
Study 23831756 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg oral ∆(9)-tetrahydrocannabinol (THC)/day
Number of subjects: 11
Study 23831756 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg oral ∆(9)-tetrahydrocannabinol (THC)/day
Number of subjects: 11
Study 23831756 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoked cannabis challenge (five puffs)
Number of subjects: 11
Study 23831756 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum cannabis smoking
Number of subjects: 11
Study 23831756 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cavity contamination after smoking or oromucosal spray
Number of subjects: 11
Study 23831756 — intervention group
Group type: EXPERIMENTAL
Intervention: THCCOOH ratios
Number of subjects: 11
Study 23831922 — intervention group
Group type: EXPERIMENTAL
Intervention: LALA94/GRAALL03-05 protocols
Number of subjects: 22
Study 23831922 — intervention group
Group type: EXPERIMENTAL
Intervention: CALM-AF10 fusion within early T-cell precursor acute lymphoblastic leukemia
Number of subjects: 22
Study 23832926 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including a health coach and enhanced personal health record
Number of subjects: 229
Study 23832926 — intervention group
Group type: COMPARATOR
Intervention: Routine discharge care (Control)
Number of subjects: 229
Study 23832926 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 229
Study 23833039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide-exposed SLE women
Number of subjects: 112
Study 23833039 — intervention group
Group type: COMPARATOR
Intervention: Control SLE women
Number of subjects: 112
Study 23833120 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly low-dose chloroquine (5 mg/kg)
Number of subjects: 132
Study 23833120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 23834234 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent lenalidomide
Number of subjects: 266
Study 23834337 — intervention group
Group type: EXPERIMENTAL
Intervention: Poststroke dementia
Number of subjects: 600
Study 23834337 — intervention group
Group type: EXPERIMENTAL
Intervention: Poststroke cognitive impairment-no dementia
Number of subjects: 600
Study 23834337 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke recurrence
Number of subjects: 600
Study 23834337 — intervention group
Group type: EXPERIMENTAL
Intervention: Death
Number of subjects: 600
Study 23834901 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3737
Study 23834999 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile device users
Number of subjects: 0
Study 23834999 — intervention group
Group type: COMPARATOR
Intervention: Traditional web browser users
Number of subjects: 0
Study 23836520 — intervention group
Group type: EXPERIMENTAL
Intervention: SAT 11βHSD1 expression in African Americans
Number of subjects: 36
Study 23836520 — intervention group
Group type: EXPERIMENTAL
Intervention: SAT 11βHSD1 expression in combined sample
Number of subjects: 36
Study 23836520 — intervention group
Group type: COMPARATOR
Intervention: SAT 11βHSD1 expression in Hispanics
Number of subjects: 36
Study 23836798 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN) performed with Symplicity Catheter System (n=6)
Number of subjects: 18
Study 23836798 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as the remaining patients who did not receive RDN)
Number of subjects: 18
Study 23837399 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (three doses)
Number of subjects: 0
Study 23837440 — intervention group
Group type: EXPERIMENTAL
Intervention: Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) questionnaire
Number of subjects: 96
Study 23837440 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Health Assessment Questionnaire (CHAQ)
Number of subjects: 96
Study 23837440 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Health Questionnaire (CHQ)
Number of subjects: 96
Study 23837440 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Utilities Index 3 (HUI3)
Number of subjects: 96
Study 23837440 — intervention group
Group type: COMPARATOR
Intervention: Comparison with other paediatric populations
Number of subjects: 96
Study 23837440 — intervention group
Group type: COMPARATOR
Intervention: General comparison with normative values
Number of subjects: 96
Study 23837759 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (TDM-1)
Number of subjects: 0
Study 23837759 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab and taxanes
Number of subjects: 0
Study 23837842 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem Cell Educator therapy
Number of subjects: 36
Study 23838219 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling catheters
Number of subjects: 7866
Study 23838219 — intervention group
Group type: EXPERIMENTAL
Intervention: External catheters
Number of subjects: 7866
Study 23838219 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall urinary catheter use
Number of subjects: 7866
Study 23838219 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute medicine wards
Number of subjects: 7866
Study 23838219 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection control reporting
Number of subjects: 7866
Study 23838767 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma patients
Number of subjects: 15
Study 23838767 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study 23838996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganetespib
Number of subjects: 0
Study 23839074 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP) 5 cmH2O with tripled tidal volume during LBNP40
Number of subjects: 14
Study 23839074 — intervention group
Group type: COMPARATOR
Intervention: Normal breathing without PEEP or tripled tidal volume during baseline
Number of subjects: 14
Study 23839074 — intervention group
Group type: COMPARATOR
Intervention: Normal breathing without PEEP or tripled tidal volume during LBNP40
Number of subjects: 14
Study 23839074 — intervention group
Group type: COMPARATOR
Intervention: Normal breathing without PEEP or tripled tidal volume during LBNP15
Number of subjects: 14
Study 23839074 — intervention group
Group type: COMPARATOR
Intervention: Lower body negative pressure (LBNP) 40 mmHg
Number of subjects: 14
Study 23839074 — intervention group
Group type: COMPARATOR
Intervention: Lower body negative pressure (LBNP) 15 mmHg
Number of subjects: 14
Study 23839484 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg co-administered with bosutinib 400 mg
Number of subjects: 24
Study 23839484 — intervention group
Group type: COMPARATOR
Intervention: Bosutinib 400 mg alone
Number of subjects: 24
Study 23840001 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial challenge with C. jejuni CG8421
Number of subjects: 15